Cidara Therapeutics, Inc.
CDTXDelisted Jan 7, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001610618
Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.
Q2 2024 vs. Q1 2024
How the institutions holding Cidara Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 50 | 26 | −24 |
| SharesConverted for a 1-for-20 split | 1.10M | 1.42M | +313.5K (+28.4%) |
| Value | $20.3M | $16.9M | −$3.42M (−16.9%) |
New holders (5)
Institutions that held Cidara Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Checkpoint Capital L.P. | 145,417 | $1.74M | 1.05% |
| Manchester Capital Management LLC | 470 | $5.61K | 0.00% |
| Royal Bank of Canada | 67 | $1.00K | 0.00% |
| Bank of America Corp | 34 | $406 | 0.00% |
| Northwestern Mutual Wealth Management Co | 14 | $167 | 0.00% |
Sold out (29)
Institutions that held Cidara Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.